Skip to main content Skip to main menu
UF Health University of Florida

College of Pharmacy

UNIVERSITY of FLORIDA

Apply to pharm.d. program
Charles Peloquin

Charles Peloquin Pharm.D.

Professor

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6266
Business Email: peloquin@cop.ufl.edu
CV: View Curriculum Vitae

About Charles Peloquin

Prior to coming to the University of Florida, Dr. Peloquin completed a hospital pharmacy residency at Duke University Medical Center, where he also served on the clinical staff. He also completed a fellowship in Infectious Diseases and Pharmacokinetics at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y. For 20 years, Dr. Peloquin was the Director of the Infectious Disease Pharmacokinetics Laboratory (IDPL) at National Jewish Medical and Research Center, Denver, CO. He now serves as Professor of Pharmacy and Medicine at UF, where the IDPL is now located. Dr. Peloquin and his lab are part of the UF Emerging Pathogens Institute. He also is a consultant to the FDA and CDC.

Honors & Awards

Member
2004-Current · International Society of Antimicrobial Pharmacology
Member
1991-Current · Society of Infectious Disease Pharmacists
Member
1990-Current · American Society of Microbiology
Member
1986-Current · American College of Clinical Pharmacy

Research Profile

Dr. Peloquin’s laboratory serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid. His research efforts focus on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.

Publications

2019
Evaluation of Super-Boosted Lopinavir/Ritonavir in combination with Rifampin in HIV-1-infected Patients with Tuberculosis
International Journal of Antimicrobial Agents
2019
Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old
Antimicrobial Agents and Chemotherapy
2019
Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing
Journal of Antimicrobial Chemotherapy
2019
A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment
Antimicrobial Agents and Chemotherapy
2019
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis
American Journal of Respiratory and Critical Care Medicine
2019
Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples
Therapeutic Drug Monitoring
2019
Isoniazid and Rifapentine Treatment Eradicates Persistent Mycobacterium tuberculosis in Macaques
American Journal of Respiratory and Critical Care Medicine
2019
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients
Antimicrobial Agents and Chemotherapy
2019
Delamanid Central Nervous System Pharmacokinetics in Tuberculous Meningitis in Rabbits and Humans
Antimicrobial Agents and Chemotherapy
2019
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection
Antimicrobial Agents and Chemotherapy
2019
Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis
Antimicrobial Agents and Chemotherapy
2019
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
American Journal of Respiratory and Critical Care Medicine
2019
Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial
PLoS Medicine
2019
Clinical Outcomes among Patients with Drug-resistant Tuberculosis receiving Bedaquiline or Delamanid Containing Regimens
Clinical Infectious Diseases
2019
Integrating pharmacokinetics and pharmacodynamics in operational research to End TB
Clinical Infectious Diseases
2019
Management of patients with multidrug-resistant tuberculosis
˜The œinternational journal of tuberculosis and lung disease (Online)
2019
Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis
Antimicrobial Agents and Chemotherapy
2019
Bacterial Factors and Relapse after Tuberculosis Therapy
New England Journal of Medicine
2019
Losartan Rescues Inflammation-Related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis
American Journal of Respiratory and Critical Care Medicine
2018
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Antimicrobial agents and chemotherapy
2018
Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis
Science Translational Medicine
2018
Protein Binding of First-Line Antituberculosis Drugs
2018
Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?"
Antimicrobial Agents and Chemotherapy
2018
Linezolid Kills Acid-Phase and Nonreplicative-Persister-Phase Mycobacterium Tuberculosis in a Hollow-Fiber Infection Model
Antimicrobial Agents and Chemotherapy
2018
Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
Antimicrobial agents and chemotherapy
2018
Evaluation of the Adequacy of Who Revised Dosages of the First-Line Antituberculosis Drugs in Children With Tuberculosis Using Population Pharmacokinetic Modeling and Simulations
Antimicrobial Agents and Chemotherapy
2018
Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.
Microbiology insights
2018
Elevated Plasma Moxifloxacin Concentrations and Slco1B1 G.-11187G > a Polymorphism in Adults With Pulmonary Tuberculosis
2018
Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-Line Antituberculosis Drugs for Children: Adequacy of Revised Dosages of Tb Drugs for Children
Pediatric Infectious Disease Journal
2018
Pharmacokinetics of Rifampicin in Adult Tb Patients and Healthy Volunteers: a Systematic Review and Meta-Analysis
The Journal Of Antimicrobial Chemotherapy
2018
Verapamil Increases the Bioavailability and Efficacy of Bedaquiline But Not Clofazimine in a Murine Model of Tuberculosis
2018
Mycobacterium Tuberculosis Strains H37Ra and H37Rv Have Equivalent Minimum Inhibitory Concentrations to Most Antituberculosis Drugs
International Journal of Mycobacteriology
2018
Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients.
Antimicrobial agents and chemotherapy
2017
Lung Tissue Concentrations of Pyrazinamide Among Patients With Drug-Resistant Pulmonary Tuberculosis
2017
Reply to Srivastava et al., "pH Conditions under Which Pyrazinamide Works in Humans"
Antimicrobial Agents and Chemotherapy
2017
Defining the Optimal Dose of Rifapentine for Pulmonary Tuberculosis: Exposure-Response Relations From Two Phase II Clinical Trials
Clinical Pharmacology & Therapeutics
2017
Polymyxin Combinations Combat Escherichia Coli Harboring Mcr-1 and Bla(Ndm-5): Preparation for a Postantibiotic Era
Mbio
2017
Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs
Journal of Pharmaceutical Sciences
2017
Population Pharmacokinetics/Pharmacodynamics of 3, 4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia
2017
An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial
Trials
2017
The Role of Therapeutic Drug Monitoring in Mycobacterial Infections
2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
2016
Population Pharmacokinetic Drug-Drug Interaction Pooled Analysis of Existing Data for Rifabutin and HIV Pis
Journal of Antimicrobial Chemotherapy
2016
Pharmacokinetics of First-Line Antituberculosis Drugs Using Who Revised Dosage in Childrenwith Tuberculosis With and Without HIV Coinfection
2016
Voriconazole Pharmacokinetics Following Hsct: Results From the Bmt Ctn 0101 Trial
Journal of Antimicrobial Chemotherapy
2016
Early Bactericidal Activity of Azd5847 in Patients With Pulmonary Tuberculosis
2016
Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-Resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands
Pediatric Infectious Disease Journal
2016
Rifapentine for the Treatment of Latent Tuberculosis
2015
Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients With Tuberculosis
2015
Population Pharmacokinetics of Rifampin in the Treatment of Mycobacterium Tuberculosis in Asian Elephants
Journal of Veterinary Pharmacology and Therapeutics
2015
Medications and Monitoring in Nontuberculous Mycobacteria Infections
Clinics in Chest Medicine
2015
Optimizing the Clinical Pharmacology of Tuberculosis Medications
Clinical Pharmacology & Therapeutics
2014
Cyp2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Pharmacotherapy
2014
Protein Binding of Rifapentine and Its 25-Desacetyl Metabolite in Patients With Pulmonary Tuberculosis
2014
Pharmacokinetic Interaction of Rifapentine and Raltegravir in Healthy Volunteers
Journal of Antimicrobial Chemotherapy
2014
Factors Associated With Variability in Rifampin Plasma Pharmacokinetics and the Relationship Between Rifampin Concentrations and Induction of Efavirenz Clearance
Pharmacotherapy
2014
A Cyp2C19 Genotype Guided Dosing Approach for Optimizing Voriconazole in Patients With Ifis.
Pharmacotherapy
2014
The Pharmacokinetics of a Single Oral Or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (Elephas Maximus)
Journal of Veterinary Pharmacology and Therapeutics
2013
Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen
2013
Therapeutic Drug Management: Is It the Future of Multidrug-Resistant Tuberculosis Treatment?
2013
Contribution of Moxifloxacin Or Levofloxacin in Second-Line Regimens With Or Without Continuation of Pyrazinamide in Murine Tuberculosis
American Journal of Respiratory and Critical Care Medicine
2013
Posaconazole Pharmacokinetics in a 2-Year-Old Boy With Rhino-Cerebral-Orbital Zygomycosis
Pharmacotherapy
2013
Preliminary Pharmacokinetic Study of Repeated Doses of Rifampin and Rifapentine in Guinea Pigs
2013
Reply To "Contradictory Results With High-Dosage Rifamycin in Mice and Humans"
2012
Rifapentine Is Not More Active Than Rifampin Against Chronic Tuberculosis in Guinea Pigs
2012
Vitamin D, Race, and Knee Osteoarthritic Pain
2012
Antituberculosis Therapy for 2012 and Beyond
Expert Opinion on Pharmacotherapy
2012
Pharmacokinetic Variability and Tuberculosis Treatment Outcomes, Including Acquired Drug Resistance
2012
Vitamin D, Race, and Experimental Pain Sensitivity in Older Adults With Knee Osteoarthritis
Arthritis and Rheumatism
2012
Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus Aureus
2012
The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium Avium Complex Disease Treatment
American Journal of Respiratory and Critical Care Medicine
2012
Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
2012
Pharmacokinetic Mismatch of Tuberculosis Drugs
2012
Prediction and in Vitro Evaluation of Selected Protease Inhibitor Antiviral Drugs as Inhibitors of Carboxylesterase 1: a Potential Source of Drug-Drug Interactions
Pharmaceutical Research
2012
Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis
2012
Paediatric Use of Second-Line Anti-Tuberculosis Agents: a Review
Tuberculosis
2012
Pharmacodynamics of Early, High-Dose Linezolid Against Vancomycin-Resistant Enterococci With Elevated Mics and Pre-Existing Genetic Mutations
Journal of Antimicrobial Chemotherapy
2011
Population Pharmacokinetics and Its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment
Current Pharmaceutical Design
2011
Activity of the Fluoroquinolone Dc-159a in the Initial and Continuation Phases of Treatment of Murine Tuberculosis
2011
Pa-824 Exhibits Time-Dependent Activity in a Murine Model of Tuberculosis
2011
Sterilizing Activity of Novel Tmc207-and Pa-824-Containing Regimens in a Murine Model of Tuberculosis
2011
Comparative Studies Evaluating Mouse Models Used for Efficacy Testing of Experimental Drugs Against Mycobacterium Tuberculosis
2011
Treatment of Tuberculosis With Rifamycin-Containing Regimens in Immune-Deficient Mice
American Journal of Respiratory and Critical Care Medicine
2010
Effects of Tuberculosis, Race, and Human Gene Slco1B1 Polymorphisms On Rifampin Concentrations
2010
The Potent Bactericidal Activity of Streptomycin in the Guinea Pig Model of Tuberculosis Ceases Due To the Presence of Persisters
Journal of Antimicrobial Chemotherapy
2010
Aminoglycoside Use in Intensive Care Units and Aminoglycoside Nephrotoxicity
2010
Bile and Gallbladder Tissue Concentrations of Moxifloxacin in Patients With Acute Cholecystitis
Annals of Pharmacotherapy
2009
Pharmacokinetic Evaluation of Rifabutin in Combination With Lopinavir-Ritonavir in Patients With Hiv Infection and Active Tuberculosis
2009
Serum Concentrations of Rifampin, Isoniazid, and Intestinal Absorption, Permeability in Patients With Multidrug Resistant Tuberculosis
2009
Population Pharmacokinetics of Linezolid in Adults With Pulmonary Tuberculosis

Grants

May 2019ACTIVE
Development of Gleevec for TB and TB/HIV
EMORY UNIV · Principal Investigator
February 2019ACTIVE
Diagnostics and Pharmacotherapy for Severe Forms of TB
UNIV OF VIRGINIA · Principal Investigator
September 2018ACTIVE
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
NATL INST OF HLTH NICHD ·
July 2018ACTIVE
An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid
EMORY UNIV · Principal Investigator
February 2018 – January 2019
Diagnostics and Pharmacotherapy for Severe Forms of TB
UNIV OF VIRGINIA · Principal Investigator
October 2017 – December 2018
Screening and Treatment of Children and Adults Exposed at Home to Drug-Resistant Tuberculosis
HARVARD MEDICAL SCHOOL · Principal Investigator
August 2017ACTIVE
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)
BOSTON UNIV · Principal Investigator
August 2016ACTIVE
Optimizing combination therapy for accelerate clinical cure of tuberculosis
NATL INST OF HLTH NIAID ·
July 2016 – May 2017
Pharmacokinetics of second-line anti-tuberculosis drugs among patients with multidrug-resistant tuberculosis
INTL SCIENCE AND TECHNOLOGY CENTER · Principal Investigator
June 2016 – August 2018
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
NATL INST OF HLTH NICHD ·
February 2016 – January 2018
A Clinical Pharmacology Study of a Novel Drug Regimen for Pre XDR and XDR Tuberculosis
EMORY UNIV · Principal Investigator
February 2016 – January 2018
MD-INMD Diagnostics and Pharmacotherapy for Service Year 2
UNIV OF VIRGINIA · Principal Investigator
September 2015 – March 2017
task A73: Combination drug testing for new TB regimens
TEXAS A&M RES FOU · Principal Investigator
August 2014 – December 2018
Rifampin and Lopinavir Study
UNIV OF MIAMI · Principal Investigator
March 2014 – June 2018
Pharmacokinetics and Pharmacodynamics of Tuberculosis Dr
CRITICAL PATH INSTITUTE · Principal Investigator
February 2014 – February 2017
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated with Efavirenz Therapy
BRIGHAM AND WOMENS HOSPITAL · Principal Investigator
February 2014 – July 2017
Immune Activation and Drug Absorption in HIV-Infected Pa
DREXEL UNIVERSITY · Principal Investigator
August 2013 – July 2018
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
BOSTON UNIV · Principal Investigator
July 2013 – June 2016
Intracavitary Drug Levels in Patients with Drug Resistan
EMORY UNIV · Principal Investigator
June 2009ACTIVE
Moxifloxain PK in Bile.
MULTIPLE SPONSORS · Principal Investigator

Education

1986
Pharm.D.
Philadelphia College of Pharmacy and Science
1981
B.S.
University of Connecticut

Contact Details

Phones:
Business:
(352) 273-6266
Lab:
(352) 273-6710
Emails:
Business:
peloquin@cop.ufl.edu
Addresses:
Mailing:
PO Box 100486
 GAINESVILLE, FL 32610
Physical:
1600 SW ARCHER RD RM P4 33
 GAINESVILLE, FL 32610